14 results about "Lymphocytic leukaemia" patented technology

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of GARP (LRRC32) by Sézary cells. GARP has also been shown to be overexpressed in samples from patients with acute lymphoblastic leukemia. GARP therefore appears as a diagnostic marker, for monitoring T-cell malignancies, and as a therapeutic target. Accordingly, the present invention relates to methods for the diagnosis and treatment of T-cell malignancies.

Disclosed in the present invention are a PIM kinase inhibitor as shown in general formula II, a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the preparation of a drug for preventing and / or treating indications related to a PIM signaling pathway. The compound of the present invention is an ideal PIM kinase inhibitor with a high activity, which can be used for treating and / or preventing diseases including autoimmune diseases and tumors, e.g., inflammatory bowel disease, hematologic malignancies such as acute myeloid leukemia, myelofibrosis and chronic lymphocytic leukemia, and solid tumors such as gastric cancer and prostate cancer.

Provided herein are methods of using 2-(2,6-dioxopiperidin-3yl)-4-(2-fluoro-4-(3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiometer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia / small lymphocytic lymphoma.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

Provided is a pharmaceutical combination comprising an antibody specific for CD19 and a natural killer cell, and a treatment method using the same. Such a pharmaceutical combination is capable of exhibiting synergistic therapeutic effects on a malignant tumor of B-cell origin such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and / or acute lymphoblastic leukemia.

The present invention relates to a tablet composition comprising Ibrutinib and one ore more pharmaceutically acceptable excipients. The invention further relates to the use of said composition as a medicament, particularly in the treatment of lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL), Waldenström's macroglobulinaemia (WM) and chronic graft versus host disease (cGVHD).

Disclosed is L-asparagine aminohydrolase and polyethylene glycol conjugate. The polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate has a high level of in vitro activity and an unexpected increase in half-life in vivo. Methods of producing the conjugate and methods of using the conjugate in therapy in treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). The method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations.

A 139-gene epigenetic signature for use in. methods for assessing the age and longevity of a T cell, selecting a T cell for a T cell therapy, and / or determining a T-cell acute lymphoblastic leukemia subtype is provided.

Provided is a method for treating chronic-phase and / or accelerated-phase and / or blast-phase chronic myelogenous leukemia and / or acute lymphoblastic leukemia in a subject by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt, crystal form, solvate or hydrate thereof. Also provided is a use of the compound of formula (I) or the pharmaceutically acceptable salt, crystal form, solvate or hydrate thereof in combination with an ATP-competitive BCR-ABL1 inhibitor.

A method of predicting the risk of progression of a cancer of a subject is described. The method can be used to infer the historical growth dynamics of an individual's cancer using fluctuating methylation clocks (FMCs). In the case of, for example, chronic lymphocytic leukaemia (CLL) (at least), the inferred growth rate holds valuable prognostic information, enabling patient stratification beyond that of standard clinical practice.

Provided are methods of treating chronic and / or accelerated and / or acute granulocytic leukemia and / or acute lymphocytic leukemia in a subject by administering to the subject a compound of Formula (I), or a pharmaceutically acceptable salt, crystalline form, solvate, or hydrate thereof. Also provided are uses of the compound of formula (I) or a pharmaceutically acceptable salt, crystal form, solvate or hydrate thereof in combination with an ATP-competitive BCR-ABL1 inhibitor. # imgabs0 #

The application provides a compound with a structure shown in a general formula (I), a deuterium compound, a stereoisomer or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same and a use thereof. The compound provided by the application has a good PIM kinase inhibition effect, is a novel, high-activity and low-toxicity ideal PIM inhibitor, and can be used for treating and / or preventing diseases such as acute myeloid leukemia, myelofibrosis, chronic lymphocytic leukemia, blood tumors such as gastric cancer and prostate cancer, and solid tumors.

This invention relates to anti-CD103 antibodies and their use in the diagnosis, prognosis, monitoring, and treatment of diseases. An imaging agent comprising the anti-CD103 antibody and a detectable label is also disclosed, wherein the antibody does not block CD103 binding to E-cadherin or at least partially blocks CD103 binding to E-cadherin. Treatment methods involve administering the anti-CD103 antibody, optionally conjugated to a cytotoxic agent. Diseases that need to be treated include, for example, hairy cell leukemia, HCLv, intestinal and extraintestinal lymphoma, enteropathy-associated T-cell lymphoma (EATL), T-lymphoblastic leukemia / lymphoma (T-ALL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia / lymphoma (ATLL), mycosis fungoides (ME), anaplastic large cell lymphoma ALCL, cutaneous T-cell lymphoma (CTCL), Cezari syndrome (SS), Alzheimer's disease, Parkinson's disease, or multiple sclerosis.

The invention relates to the field of leukemia / lymphoma diagnosis, more specifically to the detection of minimal numbers of leukemia / lymphoma cells in chronic lymphocytic leukemia (CLL) patients after therapy has started. Provided is a reagent composition for the cytometric detection of minimal residual disease (MRD) in CLL, the reagent composition comprising a panel of at least six antibodies conjugated to a detectable label, the panel comprising antibodies directed against the markers CD180, CD38, CD81, CD19, CD27 and CD5.